What is it about?
Hydralazine and valproic acid are a repositioned drugs for the cancer treatment. We have shown that the combination of both drugs inhibits the metastasis development in an experimental metastasis model, through of cell motility inhibition.
Featured Image
Why is it important?
Our objectives was determining the effect of epigenetics drugs, hydralazine and valproic acid in the metastasis development, the mechanism of this effect and the changes in the expression of metastatic modulator genes. We find that the cell motility was reduced with the treatment, and some antimetastatic genes increase their expression.
Perspectives
I will hope that this article have an impact in the future vision of the metastasis treatment, because actually only the systemic chemotherapy have some effect in the prevention of metastasis development. The drugs with an epigenetic effect have a possible role in this aspect.
Enrique Pérez-Cárdenas
Instituto Nacional de Cancerología, México
Read the Original
This page is a summary of: Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells, OncoTargets and Therapy, December 2018, Dove Medical Press,
DOI: 10.2147/ott.s187306.
You can read the full text:
Contributors
The following have contributed to this page
